ML228

SKU: orb1685433

Description

ML228 is a potent small molecule activator of the Hypoxia Inducible Factor (HIF) pathway with an EC50 of 1 μM. It effectively induces HIF signaling and its downstream target VEGF in vitro, making it a valuable research tool for studying hypoxia response, angiogenesis, and related disease models.

Research Area

Cardiovascular Research, Epigenetics & Chromatin, Metabolism Research

Key Properties

• CAS Number: 1357171-62-0
• MW: 415.49
• Purity: 99.54% (May vary between batches)
• Formula: C₂₇H₂₁N₅
• SMILES: C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1
• Target: HIF,HIF/HIF Prolyl-Hydroxylase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.81 mM);DMSO:150 mg/mL (361.02 mM)

Bioactivity

• In Vivo:
  ML228 (injection; 1 µg/kg; 7 days) treatment following spinal cord injury (SCI) improves the local hypoxic-ischemic environment, reduces SCI secondary injury, and promotes neurological function recovery.
• In Vitro:
  ML228 introduces a new chemical class for researchers exploring HIF activation and its therapeutic applications. Unlike existing HIF activators, ML228's structure significantly diverges, notably absent of the acidic functional group typically found in PHD inhibitors—an attribute potentially crucial for specific disease contexts.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ML228, ML-228, ML 228, HIF

Compound Identifiers

PubChem CID

46742353